ompany recently reported clinical and preclinical data demonstrating the therapeutic potential of a cell therapy for treating myelination disorders. Pluristem Therapeutics Inc.’s stock value also has jumped 44 per cent, on the strength of reporting a single case study in which a patient with aplastic bone marrow who received a